Grid-Enabled Measures (GEM): Overview and Lessons Learned

Advancing Data Sharing for Implementation Science in Cancer Control Workshop Day 3 June 13, 2022

NIH NATIONAL CANCER INSTITUTE

Richard P. Moser, PhD Behavioral Research Program moserr@mail.nih.gov

What is GEM?

National Cancer Institute of Health www.cancer.gov		
♦	Grid-Enabled Measures Database	Hello Rick Moser Logou
Home	Constructs Measures Datasets Workspaces About My GEM A	Admin Glossary
Canc Card Diab Educ Care HIV// Ment Nutri	collaborative, online tool to supp rospective measure (CDE) conse rocess for research and clinical s Itilizes collaborative workspaces incourages use of CDEs across p	ensus ettings sin projects
Risk and Decision Maki Sexual Behaviors Sleep	Inaugural GEM-inar! GEM Care Planning: Advancing Survivorship Care Planning In case you missed it, click the link below to watch the first GEM-inar that highlights real-world application and use of GEM. NCI's Carly Perry, PhD, MA, MSW and University of Pittsburgh's Ellen Beckjord, PhD, MPH presented on the GEM-Care More Click here to watch the Gem-inar	Center for Epidemiologic studies Depression Scale (CES-D) (Updated on 04/25/2011) Subjective Numeracy Scale (SNS) (Updated on 11/16/2010)
Smoking/Tobacco Spirituality Stress	More Community News	

What is **GEM**?

Assessment of Cancer Patient Symptoms and Needs

Overall rating of the instrument

Rating of ease of administration

Rating of ease of completion

purchase rights to use it?)

Rating of quality

Survey

https://www.gem-measures.org

National Cancer Institute

Evaluation - UK Cancer Concerns Assessmen

Instructions: Please complete this survey about the "UK Cancer Concerns Assessme

please answer regardless of whether you have used the measure or not. Question #8

instrument for clinical or research purposes. You may decline to answer any question

1. With regard to the "UK Cancer Concerns Assessment", please rate the following

Custom Measure Evaluations

1. With regard to the "UK Cancer Concerns Assessment", please rate the following:

- Overall rating of the instrument
- Rating of quality
- Rating of ease of administration
- Rating of ease of completion
- Rating of availability (e.g., is it publicly available or do you have to purchase rights to use it?)

In what context is the "UK Cancer Concerns Assessment" used? (Or could it be used? Please check all that apply)

- Clinical Practice
- Basic/Applied/Clinical Research
- Surveillance/Epidemiology

3. How useful is the "UK Cancer Concerns Assessment" for identifying otherwise unknown or undetected patient needs?

- Very useful
- Somewhat useful
- Not verv useful
- Not at all useful

U.S. National Institutes of Health I www.cancer.go

4. How useful is the "UK Cancer Concerns Assessment" to oncology and survivorship clinicians to help generate referrals to cancer rehabilitation, psychosocial care, exercise interventions, and palliative care/symptom management?

- Verv useful
- Somewhat useful
- Not very useful
- Not at all useful

5. What domains of functioning or symptoms are missing (if any) from the "UK Cancer Concerns Assessment"?

6. Can the "UK Cancer Concerns Assessment" be used for patients with all types of cancers or only specific types of cancers?

- All cancers
- Only specific types, please specify:

Iteria

7. In your opinion, will the "UK Cancer Concerns Assessment" meet the Commission on Cancer psychosocial distress screening accreditation standard?

- Yes
- No
- Unsure

8. For those who have used the "UK Cancer Concerns Assessment." in what ways has the instrument affected clinical practice (positive or negative)?

odated on

NS)

2. In what context is the "UK Cancer Concerns Assessment" used? (Or could it be used? Please check all that apply)

Wiki-based and

More Community News

Smoking/ iopacco Spirituality Stress

Rating of availability (e.g is it publicly available or do you have to

*

Past GEM Initiatives



What worked? What did not work?



- Consensus tool using crowdsourcing
 - Multiple stakeholders
- Collaborative workspaces
- Ability to find/access measures
- Wiki aspects
 - Missing/non-standard information
- Lack of data entry
 - Discomfort from users
 - Burdensome
- Disparate evaluation methods

- Data repository
- Other available resourcese.g.:
 - Data (ICPSR; CRDC)
 - Measures (NCCOR; NIH CDE Repository; PhenX; HealthMeasures)
 - Collaboration (Teams; Slack)



Lessons Learned

- Reduce burden/barriers
- Need tools and resources
- Need clear benefit to user (win/win)
 - What's the need/problem?
 - Incentivize reuse of CDEs/data
- Foster collective attitude
- Prospective vs. retrospective data harmonization
- A trusted source is important



https://here2there.ca/developing-lessons-learned/

Use Common Data Elements for More FAIR Research Data

Common data elements (CDEs) help researchers share and combine datasets, meet funding requirements, and save time.



https://cde.nlm.nih.gov/home

GEM Transition





Group-Evaluated Measures (GEM)

- Rebrand as cancer- and behaviorally-focused
- Shift to <u>dissemination</u> of existing measures
- Start with GEM initiatives then do outreach
- Search for constructs and/or measures
 - Download where possible
 - Trusted source
- Connect to other systems (e.g., HealthMeasures; PhenX; NIH CDE Repository; NCCOR)

For more information about GEM . . .



Moser et al. (2011) AJPM



www.cancer.gov/espanol

www.cancer.gov